BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ueno M, Hayami S, Shigekawa Y, Kawai M, Hirono S, Okada K, Tamai H, Shingaki N, Mori Y, Ichinose M, Yamaue H. Prognostic impact of surgery and radiofrequency ablation on single nodular HCC ⩽5 cm: Cohort study based on serum HCC markers. Journal of Hepatology 2015;63:1352-9. [DOI: 10.1016/j.jhep.2015.07.013] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 4.6] [Reference Citation Analysis]
Number Citing Articles
1 Zhang D, Duan Y, Wang Z, Lin J. Systematic profiling of a novel prognostic alternative splicing signature in hepatocellular carcinoma. Oncol Rep 2019;42:2450-72. [PMID: 31578577 DOI: 10.3892/or.2019.7342] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
2 Kim H, Lee SJ, Yoon M. Alpha-fetoprotein is correlated with intrahepatic recurrence of hepatocellular carcinoma after a hepatectomy. Ann Surg Treat Res 2020;98:168-76. [PMID: 32274364 DOI: 10.4174/astr.2020.98.4.168] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
3 Núñez KG, Sandow T, Fort D, Patel J, Hibino M, Carmody I, Cohen AJ, Thevenot P. Baseline Alpha-Fetoprotein, Alpha-Fetoprotein-L3, and Des-Gamma-Carboxy Prothrombin Biomarker Status in Bridge to Liver Transplant Outcomes for Hepatocellular Carcinoma. Cancers (Basel) 2021;13:4765. [PMID: 34638251 DOI: 10.3390/cancers13194765] [Reference Citation Analysis]
4 Wu JY, Bai XM, Wang H, Xu Q, Wang S, Wu W, Yan K, Yang W. The Perfusion Features of Recurrent Hepatocellular Carcinoma After Radiofrequency Ablation Using Contrast-Enhanced Ultrasound and Pathological Stemness Evaluation: Compared to Initial Tumors. Front Oncol 2020;10:1464. [PMID: 32983980 DOI: 10.3389/fonc.2020.01464] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 He YZ, He K, Huang RQ, Liu LW, Ye SW, Qian JL, Peng P, Luo QJ, Wang ZL, Hu ZM. A clinical scoring system for predicting tumor recurrence after percutaneous radiofrequency ablation for 3 cm or less hepatocellular carcinoma. Sci Rep 2021;11:8275. [PMID: 33859298 DOI: 10.1038/s41598-021-87782-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Lee KW, Suh SW, Choi Y, Jeong J, Yi NJ, Kim H, Yoon KC, Hong SK, Kim HS, Lee KB, Suh KS. Macrovascular invasion is not an absolute contraindication for living donor liver transplantation. Liver Transpl. 2017;23:19-27. [PMID: 27540701 DOI: 10.1002/lt.24610] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 4.8] [Reference Citation Analysis]
7 Sauzay C, Petit A, Bourgeois AM, Barbare JC, Chauffert B, Galmiche A, Houessinon A. Alpha-foetoprotein (AFP): A multi-purpose marker in hepatocellular carcinoma. Clin Chim Acta. 2016;463:39-44. [PMID: 27732875 DOI: 10.1016/j.cca.2016.10.006] [Cited by in Crossref: 91] [Cited by in F6Publishing: 94] [Article Influence: 15.2] [Reference Citation Analysis]
8 Sun J, Zhang T, Wang J, Li W, Zhang A, He W, Zhang D, Li D, Ding J, Duan X. Biologically effective dose (BED) of stereotactic body radiation therapy (SBRT) was an important factor of therapeutic efficacy in patients with hepatocellular carcinoma (≤5 cm). BMC Cancer 2019;19:846. [PMID: 31455251 DOI: 10.1186/s12885-019-6063-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
9 Wu C, Zheng L. Proteomics promises a new era of precision cancer medicine. Signal Transduct Target Ther 2019;4:13. [PMID: 31069119 DOI: 10.1038/s41392-019-0046-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 Ryu T, Takami Y, Wada Y, Tateishi M, Hara T, Yoshitomi M, Momosaki S, Yasumori K, Saitsu H, Okuda K. A Clinical Scoring System for Predicting Microvascular Invasion in Patients with Hepatocellular Carcinoma Within the Milan Criteria. J Gastrointest Surg 2019;23:779-87. [PMID: 30788712 DOI: 10.1007/s11605-019-04134-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
11 Matsuo M, Furukawa K, Shimizu H, Yoshitomi H, Takayashiki T, Kuboki S, Takano S, Suzuki D, Sakai N, Kagawa S, Nojima H, Ohsuka M. Novel treatment strategy with radiofrequency ablation and surgery for pregnant patients with hepatocellular carcinoma: a case report. Surg Case Rep 2018;4:43. [PMID: 29721779 DOI: 10.1186/s40792-018-0434-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
12 Ye K, Fan Q, Yuan M, Wang D, Xiao L, Long G, Chen R, Fang T, Li Z, Zhou L. Prognostic Value of Postoperative Circulating Tumor DNA in Patients With Early- and Intermediate-Stage Hepatocellular Carcinoma. Front Oncol 2022;12:834992. [DOI: 10.3389/fonc.2022.834992] [Reference Citation Analysis]
13 Kimura H, Ohkawa K, Miyazaki M, Sakakibara M, Imanaka K, Tamura T, Sueyoshi H, Takada R, Fukutake N, Uehara H, Ashida R, Ioka T, Nakazawa T, Nakanishi K, Katayama K. Subclassification of patients with intermediate-stage (Barcelona Clinic Liver Cancer stage-B) hepatocellular carcinoma using the up-to-seven criteria and serum tumor markers. Hepatol Int. 2017;11:105-114. [PMID: 27766479 DOI: 10.1007/s12072-016-9771-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
14 Yang F, Ma L, Yang Y, Liu W, Zhao J, Chen X, Wang M, Zhang H, Cheng S, Shen F, Wang H, Zhou W, Cao G. Contribution of Hepatitis B Virus Infection to the Aggressiveness of Primary Liver Cancer: A Clinical Epidemiological Study in Eastern China. Front Oncol 2019;9:370. [PMID: 31179237 DOI: 10.3389/fonc.2019.00370] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
15 Endo K, Kuroda H, Oikawa T, Okada Y, Fujiwara Y, Abe T, Sato H, Sawara K, Takikawa Y. Efficacy of combination therapy with transcatheter arterial chemoembolization and radiofrequency ablation for intermediate-stage hepatocellular carcinoma. Scand J Gastroenterol 2018;53:1575-83. [PMID: 30577723 DOI: 10.1080/00365521.2018.1548645] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
16 Ueno M, Nakai T, Hayashi M, Hirokawa F, Nagano H, Wada H, Kaibori M, Matsui K, Tanaka S, Yamaue H, Kubo S. Survival outcome of salvage hepatectomy in patients with local, recurrent hepatocellular carcinoma who underwent radiofrequency ablation as their first treatment. Surgery 2016;160:661-70. [PMID: 27267547 DOI: 10.1016/j.surg.2016.04.023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Tamai T, Oshige A, Tabu K, Tabu E, Ijyuin S, Sakae H, Onishi H, Muromachi K, Saisyoji A, Oda K, Kumagai K, Mawatari S, Moriuchi A, Sakurai K, Hori T, Ido A. Utility of percutaneous radiofrequency ablation alone or combined with transarterial chemoembolization for early hepatocellular carcinoma. Oncol Lett. 2017;14:3199-3206. [PMID: 28927066 DOI: 10.3892/ol.2017.6476] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
18 Pan C, Liu X, Zou B, Chin W, Zhang W, Ye Y, Liu Y, Yu J. A Nomogram Estimation for the Risk of Microvascular Invasion in Hepatocellular Carcinoma Patients Meeting the Milan Criteria. J Invest Surg 2021;:1-8. [PMID: 33655806 DOI: 10.1080/08941939.2021.1893411] [Reference Citation Analysis]
19 Liu W, Xu H, Ying X, Zhang D, Lai L, Wang L, Tu J, Ji J. Radiofrequency Ablation (RFA) Combined with Transcatheter Arterial Chemoembolization (TACE) for Patients with Medium-to-Large Hepatocellular Carcinoma: A Retrospective Analysis of Long-Term Outcome. Med Sci Monit 2020;26:e923263. [PMID: 32667906 DOI: 10.12659/MSM.923263] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
20 Lin YM, Taiji R, Calandri M, Odisio BC. Tumor Biomarkers and Interventional Oncology: Impact on Local Outcomes for Liver and Lung Malignancy. Curr Oncol Rep 2021;23:67. [PMID: 33855606 DOI: 10.1007/s11912-021-01056-4] [Reference Citation Analysis]
21 Tian M, Shi Y, Liu W, Fan J. Immunotherapy of hepatocellular carcinoma: strategies for combinatorial intervention. Sci China Life Sci 2019;62:1138-43. [PMID: 31119560 DOI: 10.1007/s11427-018-9446-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
22 Qiu J, Peng B, Tang Y, Qian Y, Guo P, Li M, Luo J, Chen B, Tang H, Lu C, Cai M, Ke Z, He W, Zheng Y, Xie D, Li B, Yuan Y. CpG Methylation Signature Predicts Recurrence in Early-Stage Hepatocellular Carcinoma: Results From a Multicenter Study. J Clin Oncol. 2017;35:734-742. [PMID: 28068175 DOI: 10.1200/jco.2016.68.2153] [Cited by in Crossref: 72] [Cited by in F6Publishing: 48] [Article Influence: 14.4] [Reference Citation Analysis]
23 Yu R, Tan Z, Xiang X, Dan Y, Deng G. Effectiveness of PIVKA-II in the detection of hepatocellular carcinoma based on real-world clinical data. BMC Cancer. 2017;17:608. [PMID: 28863782 DOI: 10.1186/s12885-017-3609-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
24 Shigekawa Y, Hayami S, Ueno M, Miyamoto A, Suzaki N, Kawai M, Hirono S, Okada KI, Hamamoto R, Yamaue H. Overexpression of KDM5B/JARID1B is associated with poor prognosis in hepatocellular carcinoma. Oncotarget 2018;9:34320-35. [PMID: 30344945 DOI: 10.18632/oncotarget.26144] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
25 Long J, Wang H, Zhao P, Sheng SP, Qin-Sheng Shi, Long M, Zheng JS. Transarterial chemoembolization combined with radiofrequency ablation for solitary large hepatocellular carcinoma ranging from 5 to 7 cm: an 8-year prospective study. Abdom Radiol (NY) 2020;45:2736-47. [PMID: 32533245 DOI: 10.1007/s00261-020-02612-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
26 Zhao Q, Wongpoomchai R, Chariyakornkul A, Xiao Z, Pilapong C. Identification of Gene-Set Signature in Early-Stage Hepatocellular Carcinoma and Relevant Immune Characteristics. Front Oncol 2021;11:740484. [PMID: 34745960 DOI: 10.3389/fonc.2021.740484] [Reference Citation Analysis]
27 Song J, Zhang F, Ji J, Chen M, Li Q, Weng Q, Gu S, Kogut MJ, Yang X. Orthotopic hepatocellular carcinoma: molecular imaging-monitored intratumoral hyperthermia-enhanced direct oncolytic virotherapy. Int J Hyperthermia 2019;36:344-50. [PMID: 30776922 DOI: 10.1080/02656736.2019.1569731] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
28 Ueno M, Hayami S, Kawai M, Hirono S, Okada KI, Miyazawa M, Kitahata Y, Miyamoto A, Suzaki N, Nakamura M, Yamaue H. Prognostic impact of adjuvant chemolipiodolization and treatment frequency on patients with hepatocellular carcinoma after hepatectomy: Prospective study with historical control group. Surg Oncol 2021;36:99-105. [PMID: 33321415 DOI: 10.1016/j.suronc.2020.12.002] [Reference Citation Analysis]
29 Tian XP, Wang CY, Jin XH, Li M, Wang FW, Huang WJ, Yun JP, Xu RH, Cai QQ, Xie D. Acidic Microenvironment Up-Regulates Exosomal miR-21 and miR-10b in Early-Stage Hepatocellular Carcinoma to Promote Cancer Cell Proliferation and Metastasis. Theranostics. 2019;9:1965-1979. [PMID: 31037150 DOI: 10.7150/thno.30958] [Cited by in Crossref: 50] [Cited by in F6Publishing: 57] [Article Influence: 16.7] [Reference Citation Analysis]
30 Beppu T, Nakagawa S, Nitta H, Okabe H, Kaida T, Imai K, Hayashi H, Koga Y, Kuramoto K, Hashimoto D, Yamashita YI, Chikamoto A, Ishiko T, Baba H. The Number of Positive Tumor Marker Status Is Beneficial for the Selection of Therapeutic Modalities in Patients with Hepatocellular Carcinoma. J Clin Transl Hepatol. 2017;5:165-168. [PMID: 28660154 DOI: 10.14218/jcth.2016.00055] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
31 Yoshida M, Ogino H, Iwata H, Hattori Y, Hashimoto S, Nakajima K, Sasaki S, Hara M, Sekido Y, Mizoe JE, Shibamoto Y. Transient increases in serum α fetoprotein and protein induced by vitamin K antagonist II levels following proton therapy does not necessarily indicate progression of hepatocellular carcinoma. Oncol Lett 2019;17:3026-34. [PMID: 30854081 DOI: 10.3892/ol.2019.9922] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
32 Huang ST, Hsu WF, Huang HS, Yen JH, Lin MC, Peng CY, Yen HR. Improved Survival in Hepatocellular Carcinoma Patients with Cardiac Arrhythmia by Amiodarone Treatment through Autophagy. Int J Mol Sci 2019;20:E3978. [PMID: 31443312 DOI: 10.3390/ijms20163978] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
33 Canale M, Ulivi P, Foschi FG, Scarpi E, De Matteis S, Donati G, Ercolani G, Scartozzi M, Faloppi L, Passardi A, Tamburini E, Valgiusti M, Marisi G, Frassineti GL, Casadei Gardini A. Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma. Critical Reviews in Oncology/Hematology 2018;129:44-53. [DOI: 10.1016/j.critrevonc.2018.06.017] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
34 Erstad DJ, Tanabe KK. Prognostic and Therapeutic Implications of Microvascular Invasion in Hepatocellular Carcinoma. Ann Surg Oncol 2019;26:1474-93. [DOI: 10.1245/s10434-019-07227-9] [Cited by in Crossref: 44] [Cited by in F6Publishing: 48] [Article Influence: 14.7] [Reference Citation Analysis]
35 Vitale A, Peck-Radosavljevic M, Giannini EG, Vibert E, Sieghart W, Van Poucke S, Pawlik TM. Personalized treatment of patients with very early hepatocellular carcinoma. J Hepatol. 2017;66:412-423. [PMID: 27677712 DOI: 10.1016/j.jhep.2016.09.012] [Cited by in Crossref: 63] [Cited by in F6Publishing: 61] [Article Influence: 10.5] [Reference Citation Analysis]
36 Casadei-Gardini A, Orsi G, Caputo F, Ercolani G. Developments in predictive biomarkers for hepatocellular carcinoma therapy. Expert Rev Anticancer Ther 2020;20:63-74. [PMID: 31910040 DOI: 10.1080/14737140.2020.1712198] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
37 Erstad DJ, Tanabe KK. ASO Author Reflections: A New Look at the Clinical Significance of MVI in Hepatocellular Carcinoma. Ann Surg Oncol 2019;26:617-8. [PMID: 31111348 DOI: 10.1245/s10434-019-07364-1] [Reference Citation Analysis]